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Summary
Human milk contains approximately 200 complex oli-
gosaccharides believed to stimulate the growth and
establishment of a protective microbiota in the infant
gut. The lack of scalable analytical techniques has
hindered the measurement of bacterial metabolism of
these and other complex prebiotic oligosaccharides.
An in vitro, multi-strain, assay capable of measuring
kinetics of bacterial growth and detailed oligosaccha-
ride consumption analysis by FTICR-MS was devel-
oped and tested simultaneously on 12 bifidobacterial
strains. For quantitative consumption, deuterated and
reduced human milk oligosaccharide (HMO) stan-
dards were used. A custom software suite developed
in house called Glycolyzer was used to process the
large amounts of oligosaccharide mass spectra auto-
matically with 13C corrections based on de-isotoping
protocols. High growth on HMOs was characteristic
of Bifidobacterium longum biovar infantis strains,
which consumed nearly all available substrates, while
other bifidobacterial strains tested, B. longum bv.
longum, B. adolescentis, B. breve and B. bifidum,
showed low or only moderate growth ability. Total
oligosaccharide consumption ranged from a high
of 87% for B. infantis JCM 7009 to only 12% for
B. adolescentis ATCC 15703. A detailed analysis of
consumption glycoprofiles indicated strain-specific
capabilities towards differential metabolism of milk
oligosaccharides. This method overcomes previous
limitations in the quantitative, multi-strain analysis of
bacterial metabolism of HMOs and represents a novel
approach towards understanding bacterial consump-
tion of complex prebiotic oligosaccharides.
Introduction
Understanding the molecular details of the metabolism of
dietary oligosaccharides by gut microorganisms is impor-
tant for elucidating their role in modulating health and
disease. Dietary oligosaccharides are found abundantly in
plants, fruits and are the third largest solid component of
human milk (Coppa et al., 2004). The structural complex-
ity of these oligosaccharides ranges widely among natural
products, and results from the combination of the different
monomeric glycosyl units forming mixtures differing in
their degree of polymerization and glycosidic linkages.
Many oligosaccharides readily extractable from natural
products may function as prebiotics: ‘nondigestible food
ingredients that beneficially affect the host by selectively
stimulating the growth and/or activity of one or a limited
number of bacterial species already resident in the colon,
and thus attempt to improve host health’ (Gibson and
Roberfroid, 1995). Since its initial definition in 1995 a
growing number of food components, including many
plant-derived non-digestible dietary fibres, have been
claimed to elicit a prebiotic effect (Mussatto and Mancilha,
2007), however there is relatively little experimental detail
on their specific metabolism by beneficial bacteria, or
probiotics. Recently, stricter criteria for the classification of
food ingredients as prebiotics have been established
(Roberfroid, 2007) which emphasize the requirement for a
selective and specific modulation of beneficial microor-
ganisms in the gastrointestinal tract. Therefore, the next
generation of prebiotics will require a clear understanding
of the oligosaccharide structural complexity needed to
selectively enrich growth of very specific beneficial bacte-
rial communities for treating particular disease states or
promoting specific wellness attributes.
While in exclusively breast-fed infants bifidobacteria
can comprise up to 90% of the infant gut microbiota, in
formula-fed infants a more complex and adult-like micro-
biota is generally observed (Favier et al., 2003). Oral
supplementation of Bifidobacterium longum bv. infantis
(B. infantis) and Lactobacillus acidophilus significantly
reduced the incidence and severity on necrotizing entero-
colitis in very low-birth-weight (< 1500 g) infants (Lin
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et al., 2005). High levels of bifidobacteria in the new-
borns’ gut microbiota are associated with reduced levels
of intestinal infections and diarrhoea, and the benefits
include a barrier effect against pathogens, the develop-
ment of the infant gut immune system and an increased
lactose tolerance (Lievin et al., 2000; Ouwehand et al.,
2002; Servin, 2004). Human milk contains between 3 and
20 g l-1 (Coppa et al., 1993) of complex oligosaccharides
necessary to stimulate early colonization of the undevel-
oped infant gut by bifidobacteria (Chaturvedi et al., 2001).
Human milk oligosaccharides (HMOs) consist of a
lactose core extensively elongated by b1-3 or b1-6 link-
ages to lactosamine units, and further decorated with
fucose or sialic acid residues in terminal positions con-
nected respectively with a1-2,3,4 and a2-3,6 linkages.
The possible arrangement of monosaccharide combina-
tions and linkages results in a structurally complex array
of linear and branched oligosaccharide structures. The
latest annotation of the human milk glycome utilized a
high mass accuracy analyser (orthogonal time of flight
mass spectrometry) to identify approximately 200
molecular species based on exact mass measurements
from a pooled human milk sample (Ninonuevo et al.,
2006). An understanding of the biological function of
HMO and their beneficial health effects on infants, aside
from their postulated prebiotic role (LoCascio et al.,
2007), has only recently begun to emerge (Bode, 2006).
HMOs have an immunomodulatory effect on neutrophils
(Bode et al., 2004). They have been shown to decrease
binding and infection of the pathogen Campylobacter
jejuni (Ruiz-Palacios et al., 2003) and inhibit HIV-1 trans-
fer to CD4+ T lymphocytes (Hong et al., 2008). Recently
our group described a strategy to annotate the human
milk glycome, and identified nearly 200 possible oligosac-
charide structures differing in their size, charge and
sequence (Ninonuevo et al., 2006). Mass spectrometric
methods were developed to monitor bacterial consump-
tion of individual HMOs (Ninonuevo et al., 2007), and
demonstrated specific, preferential oligosaccharide con-
sumption by select bifidobacterial strains, providing a
rationale for why microorganisms, such as B. infantis,
are uniquely enriched in the gut of breast-fed infants
(LoCascio et al., 2007).
Unfortunately, the limited quantification methods to
analyse complex HMOs had hindered our understanding
of their metabolism by bifidobacterial species and other
specific biological functions associated with these
complex oligosaccharides. In this report, a method for
rapid and detailed analysis of bifidobacteria for their
capacity to consume the most abundant fucosylated and
neutral HMOs was developed. The method is an inte-
grated, scalable platform using a combination of microtitre
plate analysis of microbial growth and MALDI-FTICR-MS
to obtain detailed, strain-specific oligosaccharide con-
sumption profiles. To handle the large amounts of data
generated from the mass spectrometer, a high-throughput
data analysis software package, Glycolyzer, was devel-
oped in house. The Glycolyzer software suite was written
in Igor Pro 6.04 (WaveMetrics, Portland, OR) to facilitate
data processing from raw mass spectra to analysed data.
Analysis included signal noise filtering, isotope deconvo-
lution, oligosaccharide peak annotation and deuterated/
undeuterated (D/H) relative quantification. This method
can be extended towards the analysis of microbial con-
sumption of other complex dietary oligosaccharides, and
will be particularly useful when the substrate is of limited
availability and information on specific oligosaccharide
consumption from complex mixtures of oligosaccharides
is demanded. The method presented here enables
detailed profiling of probiotic bacterial culture collections
for their ability to metabolize complex milk oligosaccha-
rides. This method forms part of a strategy to identify the
symbiotic effect between specific probiotic bacterial
strains and the type of prebiotic dietary carbohydrate nec-
essary to treat specific health conditions.
Results
A plate reader-based bacterial growth assay was coupled
with MS analysis of the spent cultures, and a custom-
developed data analysis software to obtain detailed HMO
consumption patterns for 12 bifidobacterial strains. For
every strain, the following growth kinetics parameters
were calculated: growth rate, apparent lag time, genera-
tion time and maximum optical density (OD) reached.
These were analysed in combination with the HMO con-
sumption glycoprofiling data to obtain a detailed descrip-
tion of each strain’s ability to metabolize specific HMOs. In
the automated MS analysis error bars were calculated
from at least six relative standard deviations of both the
control and samples. Computing the propagation of error
was necessary because the per cent HMO consumption
was computed by normalizing the MS intensity of the
samples to that of the control. Per cent relative standard
deviation widely ranged from 1% to 18% and an average
of less than 10% for each oligosaccharide peak. The
combined use of 96-well plates and TipTop cartridges
reduced the amount of HMO needed for bacterial growth
by fivefold, and has reduced the time to perform the
oligosaccharide extraction process of a given sample
from 41.5 to 3.5 h (Fig. 1). This method enabled monitor-
ing bacterial consumption of the most abundant fucosy-
lated and neutral oligosaccharide isomers in human
breast milk, accounting by number for 54% of the total
number of individual oligosaccharides from a pooled
human milk sample. The HMO masses monitored
comprise several isomers representing the highest
abundance milk oligosaccharides, and accounting for
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approximately 70% of all HMOs in milk (Ninonuevo et al.,
2006) (Table S1).
Glycan-specific growth of B. infantis strains
The highest growth was observed mainly among the
B. infantis strains JCM 7009, JCM 7010, JCM 7007, JCM
7011 and ATCC 15697, respectively, for which a nearly
complete consumption of all HMOs with a DP (degree of
polymerization of the HMOs)  7 (m/z = 732.25, 878.31,
1097.39 and 1243.44) was observed (Table 1, Figs 2
and S1). Among these strains the HMO consumption pat-
terns resulted in highly similar glycoprofiles and the total
HMO utilization ranged between 87.15% and 84.08%
(Table 1). Except ATCC 15697, the rest of the strains have
been classified by ribotyping and RAPD-PCR to belong
to the infantis biovar (Sakata et al., 2002). Compared
with other bifidobacterial species tested these B. infantis
strains shows unique glycoprofiling patterns with very
high metabolic capacity for HMOs. This is also clearly
reflected in their growth kinetic analysis for having dis-
tinctly similar growth rates and the highest ODs achieved
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Fig. 1. Schematic of experimental procedure. Schematic illustration for the workflow utilized for the real-time monitoring of bacterial growth,
sample preparation, MS analysis, data collection and analysis. (a and b) Clonal expansion and real-time monitoring of bacterial growth
performed in anaerobic chamber. (c) Sample collection. (d) Sample inactivation, sterilization and clean-up. (e) Internal standard addition. (f)
TipTop PGC oligosaccharide isolation. (g) Sample MS analysis, data acquisition and processing. Time gains in sample processing as
compared with a previously developed method (LoCascio et al., 2007).
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among all the tested strains. Deuterated and reduced milk
oligosaccharides were added as internal standards
(Fig. 3) and Glycolyzer was used to perform automatic
calculations of D/H ratios which were used as metric for
measuring specific oligosaccharide consumption. HPLC-
Chip/TOF-MS analysis of B. infantis ATCC 15697 oli-
gosaccharide consumption patterns confirmed previous
MALDI-FTICR-MS data (LoCascio et al., 2007) indicating
Table 1. Kinetic analysis of bacterial growth.
Strain
Growth Rate
(1/hr) STD
Lag time
(hrs) STD
Generation
time (hrs) STD
Max. OD
(600 nm) STD
% HMO
consumed
B. infantis JCM 7009 2.06E-01 1.2E-03 21.01 5.2E-03 1.46 3.4E-03 1.26 0.02 87.15
B. infantis ATCC 15697 1.24E-01 1.7E-03 24.46 3.1E-02 2.43 1.3E-02 1.12 0.05 86.74
B. infantis JCM 7010 1.06E-01 1.6E-03 25.10 2.1E-02 2.83 1.7E-02 0.94 0.09 85.65
B. infantis JCM 7007 1.06E-01 1.9E-03 24.57 2.7E-02 2.83 2.0E-02 1.10 0.03 84.89
B. infantis JCM 7011 1.05E-01 7.1E-04 20.25 1.5E-02 2.86 7.9E-03 1.09 0.05 84.08
B. infantis JCM 1260 7.65E-02 3.1E-04 35.58 7.5E-03 3.94 6.5E-03 0.65 0.01 47.72
B. bifidum JCM 1254 6.50E-02 7.9E-04 24.03 6.0E-02 4.63 2.3E-02 0.92 0.25 16.26
B. infantis JCM 11347 2.83E-02 2.8E-04 11.05 3.3E-02 10.63 4.4E-02 0.48 0.02 33.54
B. breve ATCC 15700 2.32E-02 3.3E-04 20.30 7.8E-02 12.99 7.5E-02 0.44 0.15 39.06
B. longum ATCC 15707 1.06E-02 1.8E-04 16.93 8.5E-02 28.47 2.0E-01 0.51 0.03 29.79
B. bifidum JCM 1255 3.82E-03 2.8E-05 31.46 4.4E-02 78.79 2.3E-01 0.21 0.01 11.11
B. adolescentis ATCC 15703 – – – 0.08 0.00 12.27
Growth rate, lag time and generation time were calculated using the Bacterial Growth Kinetics Software package (F. Breidt, pers. comm.). Max.
OD represents the last absorbance reading before samples were collected for analysis. % HMO consumed was calculated by taking into account
the relative abundances of each HMO consumed (Table S1). All strains were grown in triplicate. Dark grey/light grey/no shading = high/medium/low
HMO consumers.
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Fig. 3. MALDI-FTICR-MS analysis of glycans remaining post fermentation by B. adolescentis (A) and B. infantis (B). Shown in the upper
section are the full scan MS of the two samples along with the zoomed-in mass spectra of four selected masses [m/z 1097 (1), 1243 (2), 1608
(3), 1754 (4)]. The lines point to the difference of the D/H ratio for each sample illustrating differential consumption of the two species (see text
for details on the D/H methods).
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that among several HMOs available B. infantis consumes
only specific glycans. The HPLC-Chip/TOF-MS system
enabled the detailed HMO consumption analysis at the
single isomer level revealing that B. infantis does not
discriminate among isomers of the same HMO (Fig. 4).
Noticeable differences in both consumption glycopro-
files and all kinetic parameters were observed for B. infan-
tis strains JCM 11347 and JCM 1260 which only partially
consumed HMOs with DP  7. Additionally, strain JCM
11347 did not utilize fucosylated HMOs with an m/z of 878
and 1389. These HMOs differ by the addition of fucosy-
lated Lacto-N-Biose units as described in LoCascio and
colleagues (2007). For oligosaccharides with a DP  7 no
consumption differences were observed among all the B.
infantis strains. Comparatively, while JCM 7009 utilized
75% of the total HMO consumed from oligosaccharides
with a DP  7, JCM 11347 only achieved 25% consump-
tion from the same HMOs. Strains JCM 1260 and JCM
11347 achieved mediocre growth on HMOs with an OD
0.65 and 0.48, respectively, corresponding approximately
to half of the typical OD of B. infantis strains optimally
growing on HMOs (Table 1). The growth kinetic param-
eters of these two B. infantis strains closely resemble that
from non-B. infantis strains which also poorly metabolized
HMOs. Although most B. infantis strains achieved excel-
lent growth on HMOs, strains JCM 1260 and JCM 11347
were an exception, which was reflected in their subopti-
mal growth kinetics. A key factor determining their lack
of growth could be their inability to efficiently consume
HMOs with an m/z of 732 and 878, representing 41.9%
and 25.9% of the total HMOs measured in our assay
(Table S1). Due to the large abundance of these two
oligosaccharides in the pooled milk sample, the strains’
inability to consume them would greatly undermine their
growth.
Glycan-specific growth of non-B. infantis strains
For the two Bifidobacterium bifidum strains tested, JCM
1254 and JCM 1255, although similar glycoprofiles
patterns and HMO consumption rates were observed
(Fig. 2), these strains differ in their overall growth kinetics
(Table 1). While JCM 1254 consumed only 16.26% of the
total HMOs, this strain grew moderately on this substrate
and achieved an OD of 0.9. It is likely that JCM 1254 is
able to grow on sialylated HMOs or on less abundant, yet
numerically significant, neutral and acidic HMOs which
are not being monitored in our assay.
Bifidobacterium breve ATCC 15700 consumed 64.5%
of Lacto-N-(neo)tetraose (m/z = 732), and 20% of the
fucosylated HMOs not consumed by ATCC 15707 and
JCM 11347 (Fig. 2). The combined metabolism of these
oligosaccharides in ATCC 15700 accounts for 33.7% of
the total HMO consumption and enables this organism to
Fig. 4. HPLC-Chip/TOF-MS analysis of selectivity for specific glycan structures consumed by B. infantis ATCC 15697. Shown are nanoLC
extracted ion chromatograms (XIC) of selected milk glycans recovered (A) after incubation with B. infantis ATCC 15697 and (B) before
incubation (control). The complete disappearance (A) of all glycan peaks for specific oligosaccharide (m/z: 732, 878 and 1243) indicates that
B. infantis consumes specific HMOs but does not discriminate for any specific isomers within each group of HMO consumed.
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achieve growth kinetics similar to ATCC 15707 and JCM
11347. Interestingly, B. infantis JCM 11347 and B. longum
ATCC 15707, having nearly identical glycoprofiles, similar
growth kinetics and an overall HMO consumption of,
33.5% and 29.8%, respectively, do not consume fucosy-
lated HMOs with m/z of 878 and 1379. This indicates that
the metabolism of fucosylated HMOs in some but not all
bifidobacteria can be an important factor for their overall
efficiency in oligosaccharide consumption, ultimately
affecting their growth.
With the exception of B. bifidum JCM 1255 and B.
adolescentis ATCC 15703 which possess a very limited
ability to metabolize HMOs, the rest of the tested strains,
differentially utilized HMOs with a DP  7. However a
similar consumption pattern for HMOs with a DP  8 was
observed for all the tested strains, regardless of their
growth kinetics and total HMO consumption (Fig. 2).
Discussion
A MALDI-FTICR-MS method (LoCascio et al., 2007) was
made scalable to enable the fast analysis of growth and
consumption by several bifidobacterial strains of the most
abundant neutral and fucosylated HMOs. The growth
kinetics analysis, the multi-sample, small-volume post-
fermentation oligosaccharide extraction process, and
custom-developed software for MS oligosaccharide data
analysis are key novelties of this method. The software
tool developed utilized statistical spectra processing and
data reconstructive algorithms to rapidly annotate, identify
and quantify spectral peaks generated by the MS analy-
sis. The integration of these previously independent
modules into a single, integrated platform enabled the
simultaneous, fast, multi-strain analysis for bacterial
metabolism of individual oligosaccharides in complex pre-
biotic mixtures. The significant sample processing time
gains, and the critical 30-fold reduction in sample volume
and HMO usage, compared with a previously published
method (LoCascio et al., 2007), enabled the study of con-
sumption of complex milk oligosaccharides in several bifi-
dobacterial strains in a single experiment. This report is
the first describing the use of HPLC-Chip/TOF-MS micro-
fluidic technology to profile bacterial consumption of indi-
vidual glycan isomers from a complex mixture of prebiotic
oligosaccharides.
The noticeable differences in overall growth kinetics,
consumption glycoprofiles and per cent HMO consumed,
both within and across bifidobacterial species, indicate
that there are strain-specific differences in the respective
abilities and efficiencies of HMO metabolism. Overall, the
key measures of bacterial growth, such as the growth
rate and maximum OD, correlate well with total per cent
HMO consumed and the specific consumption of abun-
dant HMOs, such as Lacto-N-Tetraose (m/z = 732.25)
and Lacto-N-Hexaose (m/z = 1097.39). The extended
lag time observed for all the tested strains (Table 1) is
likely caused by the switch from lactose, a preferred
(Parche et al., 2006) and easily metabolized disaccha-
ride present in the pre-culturing MRS media, to a
lactose-free HMO-based medium containing complex oli-
gosaccharides with a DP  4. Based on these results
the tested strains can be grouped into high (ATCC
15697, JCM 7011, JCM 7010, JCM 7009, JCM 7007),
medium (ATCC 15700, ATCC 15707, JCM 1260, JCM
1347, JCM 1254) and low HMO consumers (ATCC
15703, JCM 1255) (Table 1). The nearly complete con-
sumption by the high-HMO-consuming strains of glycans
with a DP  8 (Fig. 2) suggests that these B. infantis
strains posses a highly specialized, size-specific system
for binding and import of HMOs with DP  8. Indeed,
analysis of the B. infantis ATCC 15697 genome has
revealed the presence of extracellular solute-binding pro-
teins (SBP) predicted to bind oligosaccharides and part
of an ABC transporter system complex. In comparison,
B. infantis ATCC 15697 possesses 21 such genes
associated with oligosaccharide transport, while B.
adolescentis ATCC 15703 (GenBank: AP009256) only
possesses 11. Additionally, the clustering of some of
these transport proteins around b-galactosidases,
N-acetyl-b-hexosaminidases, sialidases and fucosidases
suggests a common role and co-regulation in the import
and metabolism of HMOs (Sela et al., 2008). Notably,
strains belonging to the B. infantis biovar dominated as
high HMO consumers; their superior ability to consume
prebiotic oligosaccharides from human milk is likely an
essential trait enabling this species to be one of the most
abundant early colonizers of the breast-fed infant gut
(Favier et al., 2003).
HMOs are an abundant component of diets in breast-fed
infants. The differential growth of several bifidobacterial
species on this complex substrate supports the principle
that the prebiotic effect of human milk directs selected
bacterial communities and assigns milk’s microbiota alter-
ing properties to its oligosaccharides. Precise identification
and quantification of oligosaccharide consumption by indi-
vidual gut bacteria enables an in-depth understanding of
their metabolism by probiotic organisms. The increasing
availability of sequenced microbial genomes creates an
opportunity for glycomics methods such as the one
described here, to provide the functional characterization
needed to support comparative genome analyses and
gene expression studies. Together they enable the under-
standing at the molecular and genetic level of prebiotic
consumption and metabolism by gut bacteria. While all
these methods are limited by their in vitro and in silico
approaches, they are critical tools to design and select
optimal prebiotic–probiotic combinations, prior to perform
animal and human efficacy studies.
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Experimental procedures
HMO purification
HMOs were separated from pooled human breast milk
samples as previously described in Ward and colleagues
(2006). Pooled milk was provided by ProLacta Biosciences
(Monrovia, CA).
Microtitre growth of bacteria
All bifidobacterial strains were obtained from the Japanese
Collection of Microorganism (JCM) or the American Type
Culture Collection (ATCC) (Manassas, VA). Cultures were
initially propagated on deMan, Rogosa, Sharpe, (MRS) agar
plates (Becton Dickinson, Sparks, MD). Single colonies were
picked with a 1 ml sterile loop and smeared on the bottom of a
Corning (Lowell, MA) untreated polystyrene 96-well plate
(Fig. 1, a), then grown twice on a semi-synthetic MRS
medium, devoid of a carbohydrate source (Barrangou et al.,
2003). In the first passage this medium was supplemented
with 1.5% (w/v) filter-sterilized (Millex-GV, 0.22 mm, Millipore,
Billerica, MA) lactose as the sole carbohydrate source. The
resulting cultures were then used as a 1% inoculum for a
second passage where the medium was supplemented with
1.6% (w/v) sterile-filtered HMO (Fig. 1, b). All wells were
covered with 40 ml of sterile mineral oil to prevent evaporation
during the growth assays. Cell growth was performed in 100 ml
of HMO-supplemented media and monitored in real time by
assessing optical density at 600 nm (OD600) using a BioTek
PowerWave 340 plate reader (Winoosky, VT). The plate
reader was operated in discontinuous mode, with absorbance
readings performed in 30 min intervals, and preceded by 30 s
shaking intervals at medium speed. There was no detectable
growth on this medium (OD600 < 0.1) without the addition of a
carbohydrate source. All media were also supplemented with
1% (w/v) L-cysteine and all incubations and sample collec-
tions were carried out at 37°C in an anaerobic chamber (Coy
Laboratory Products, Grass Lake, MI). All the collected data
were processed with the Bacterial Growth Kinetics Software
(F. Breidt, pers. comm.), curve fitting was performed using the
Logistic model, and all other parameters were set to default.
Samples were grown in biologically independent triplicates
and the resulting growth kinetic data were expressed as the
mean of these replicates with the respective standard devia-
tion. Controls consisted of inoculated medium lacking HMO
and un-inoculated medium containing HMO.
Preparation of spent cultures for MS analysis
Cell growth was monitored every 30 min as previously
described; upon reaching stationary phase the cells superna-
tants were collected anaerobically (Fig. 1, c). The resulting
spent supernatant was heat inactivated at 100°C for 5 min in a
PTC-200 MJ Thermocycler (Bio-Rad Laboratories, Hercules,
CA) and filter sterilized using a filter plate with 0.45 mm diam-
eter (MultiScreen HTS-HV, Millipore) (Fig. 1, d). HMO stability
under these conditions has been previously verified (data not
shown). Samples were stored at -80°C until further use.
Oligosaccharide isolation and purification
Oligosaccharides from supernatants were recovered and
purified as described in LoCascio and colleagues (2007) with
the following modifications: 2.0 M sodium borohydride (20 ml)
was added to 20 ml of sterile-filtered spent supernatant
and incubated at 65°C for 1 h (Fig. 1, e). Five ul
(50.0 mg ml-1) of deuterated and reduced milk oligosaccha-
rides was added as internal standards. The mixture was
desalted and purified by solid-phase extraction using TopTip
(100–1000 ml capacity) packed with graphitized carbon
(Glygen, Columbia, MD). The tip was conditioned by washing
three times with 400 ml of deionized water, followed by
washes with 80% acetonitrile in 0.10% (v/v) aqueous trifluo-
roacetic acid (TFA) (v/v) and nanopure water. The sample
was then loaded onto the tip and subsequently washed seven
times with 400 ml of nanopure water and eluted with 400 ml of
20% (v/v) acetonitrile in water. The fraction was dried in
vacuo and reconstituted with 50 ml of nanopure water prior to
MS analysis (Fig. 1, f).
MS methods
MALDI-FTICR-MS analysis. Mass spectra were acquired
using a ProMALDI-FTICR-MS (Varian, Lake Forest, CA)
equipped with an external MALDI source, a Nd:YAG laser
(355 nm) and a 7.0 Tesla shielded-superconducting magnet.
Sample (1 ml) was applied onto a stainless steel MALDI
target, doped with 1 ml of 0.01 M sodium chloride and fol-
lowed by 1 ml of 0.4 M 2,5-dihydroxybenzoic acid (matrix).
Two MS acquisitions (at least) were recorded for each bio-
logical replicate. MALDI-FTICR-MS analysis was performed
in the m/z scan range of 220–4500 with 1024K data points
and 1 MHz ADC rate acquired in the positive ionization mode.
HPLC-Chip/TOF-MS analysis. Pooled HMOs were analysed
following the method published previously (Ninonuevo et al.,
2006). Isolated oligosaccharides from pooled human milk
were profiled using an Agilent 6200 Series HPLC-Chip/
TOF-MS system equipped with a microwell-plate autosam-
pler (maintained at 20.0°C), capillary sample loading pump,
nanopump, HPLC-Chip interface and the Agilent 6210 TOF
LC/MS. The glycan chip used consisted of 40 nl enrichment
column and 43 ¥ 0.75 mm ID analytical column, both packed
with porous graphitized carbon 5 mm stationary phase. The
sample in 0.1% formic acid (0.5 ml) was delivered isocratically
via capillary pump in 3.0% (v/v) acetonitrile/water at
4 ml min-1. Subsequently, a nanolitre pump gradient was run
at 0.3 ml min-1 consisting of (A) 0.1% formic acid in 3.0%
acetonitrile/water (v/v) and (B) 0.1% formic acid in 90%
(v/v) acetonitrile/water. A 45 min nanoLC gradient was run
at 0–16% B, 2.5–20.0 min, 16–44% B, 20.0–30.0 min,
44–100% B, 30.0–35.0 min with equilibration time of 20 min
at 0% B. The drying gas temperature was set at 325°C with
a flow of 4.0 l min-1 (2 l of filtered nitrogen gas and 2 l of
filtered dry grade compressed air). Data were acquired in the
positive ionization mode within a mass range of m/z 500–
3000. Mass correction was enabled using a reference mass
of m/z 519.139.
Analytical algorithm for HMO annotation
Custom data analysis software was designed due to the
uniqueness and magnitude of the problem. The software was
designed to process ASCII mass spectra or ion cyclotron
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resonance transients from the mass spectrometer and calcu-
late D/H ratios as a metric for measuring specific oligosac-
charide consumption.
Data preprocessing was required to centroid peaks and
calculate lower limit of detection abundance thresholds. Accu-
rate mass assignments and intensities were obtained by fitting
a parabola to the three highest points in a peak. The apex of
the fit parabola provides the abundance and centroid mass of
a peak. The signal detection noise threshold was set at six
standard deviations above the mean. Baseline noise peaks
are often the most frequently detected peaks in a spectrum. A
histogram of all abundances provides an approximation of the
distribution of the noise. The standard deviation of the noise is
calculated from the half width at half maximum of the distribu-
tion. The centroided data needed to be reduced to monoiso-
topic peaks before D/H ratios were calculated. A data
reconstructive fitting algorithm was used for monoisotopic
peak location determination. Synthetic isotope calculations
were based on a sugar ‘averagose’ calculations rather than the
common ‘averagine’ model since the peptides basis is not
fitting for oligosaccharides. The sugar ‘averagose’ building
block used was based on a general HexNAc monosaccharide
unit C8H13O5N1 (MW = 203.07937 g mol-1). The HexNAc
averagose approximation provided an effective model for the
experimental isotope distributions as noted from the libraries
or exact elemental compositions. The averagose was led to
elemental compositions by multiplying the averagose by a
factor to obtain the theoretical carbon, hydrogen, oxygen and
nitrogen composition of the unknown ion. Once the estimated
elemental composition was found, a synthetic isotopic distri-
bution was calculated using Poisson’s distribution. Numerical
methods were used to reconstruct the overlapping deuterated
and non-deuterated isotopic distributions and yield the
monoisotopic peaks for D/H ratio calculations. Once the
monoisotopic ions were located after data reconstruction, the
non-deuterated synthetic distribution was subtracted to calcu-
late the deuterated monoisotopic sugar abundance. The auto-
mated D/H analysis performed with the Glycolyzer algorithms
was consistent with manual calculations performed by hand.
Acknowledgements
This work was partially funded by grants from the California
Dairy Research Foundation (CDRF), Dairy Management Inc.,
UC Discovery and USDA NRI-CSREES Award 2008-35200-
18776. This research was partially supported by an industry/
campus-supported fellowship (R.G.L.) under the Training
Program in Biomolecular Technology (T32-GM08799) at
the University of California, Davis. Agilent Technologies is
thanked for providing the HPLC-Chip/TOF-MS system and Dr
Fred Breidt at the USDA – ARS for the Bacterial Growth
Kinetics Software package.
References
Barrangou, R., Altermann, E., Hutkins, R., Cano, R., and
Klaenhammer, T.R. (2003) Functional and comparative
genomic analyses of an operon involved in fructooligosac-
charide utilization by Lactobacillus acidophilus. Proc Natl
Acad Sci USA 100: 8957–8962.
Bode, L. (2006) Recent advances on structure, metabolism
and function of human milk oligosaccharides. J Nutr 136:
2127–2130.
Bode, L., Rudloff, S., Kunz, C., Strobel, S., and Klein, N.
(2004) Human milk oligosaccharides reduce platelet-
neutrophil complex formation leading to a decrease in
neutrophil beta 2 integrin expression. J Leukoc Biol 76:
820–826.
Chaturvedi, P., Warren, C.D., Buescher, C.R., Pickering, L.K.,
and Newburg, D.S. (2001) Survival of human milk oligosac-
charides in the intestine of infants. In Bioactive Compo-
nents of Human Milk. Newburg, D.S. (ed.). New York:
Kluwer Academic, pp. 315–323.
Coppa, G.V., Gabrielli, O., Pierani, P., Catassi, C., Carlucci,
A., and Giorgi, P.L. (1993) Changes in carbohydrate-
composition in human-milk over 4 months of lactation.
Pediatrics 91: 637–641.
Coppa, G.V., Bruni, S., Morelli, L., Soldi, S., and Gabrielli, O.
(2004) The first prebiotics in humans – human milk oli-
gosaccharides. J Clin Gastroenterol 38: S80–S83.
Favier, C.F., de Vos, W.M., and Akkermans, A.D.L. (2003)
Development of bacterial and bifidobacterial communities
in feces of newborn babies. Anaerobe 9: 219–229.
Gibson, G.R., and Roberfroid, M.B. (1995) Dietary modula-
tion of the human colonic microbiota – introducing the
concept of prebiotics. J Nutr 125: 1401–1412.
Hong, P., Ninonuevo, M.R., Lee, B., Lebrilla, C.B., and Bode,
L. (2008) Human milk oligosaccharides reduce HIV-1-
gp120 binding to dendritic cell-specific ICAM3-grabbing
non-integrin (DC-SIGN). Br J Nutr (in press).
Lievin, V., Peiffer, I., Hudault, S., Rochat, F., Brassart, D.,
Neeser, J.R., and Servin, A.L. (2000) Bifidobacterium
strains from resident infant human gastrointestinal microf-
lora exert antimicrobial activity. Gut 47: 646–652.
Lin, H.C., Su, B.H., Chen, A.C., Lin, T.W., Tsai, C.H., Yeh,
T.F., and Oh, W. (2005) Oral probiotics reduce the inci-
dence and severity of necrotizing enterocolitis in very low
birth weight infants. Pediatrics 115: 1–4.
LoCascio, R.G., Ninonuevo, M.R., Freeman, S.L., Sela, D.A.,
Grimm, R., Lebrilla, C.B., et al. (2007) Glycoprofiling of
bifidobacterial consumption of human milk oligosaccha-
rides demonstrates strain specific, preferential consump-
tion of small chain glycans secreted in early human
lactation. J Agric Food Chem 55: 8914–8919.
Mussatto, S.I., and Mancilha, I.M. (2007) Non-digestible
oligosaccharides: a review. Carbohydr Polym 68: 587–
597.
Ninonuevo, M.R., Park, Y., Yin, H., Zhang, J., Ward, R.E.,
Clowers, B.H., et al. (2006) A strategy for annotating the
human milk glycome. J Agric Food Chem 54: 7471–7480.
Ninonuevo, M.R., Ward, R.E., LoCascio, R.G., German, J.B.,
Freeman, S.L., Barboza, M., et al. (2007) Methods for the
quantitation of human milk oligosaccharides in bacterial
fermentation by mass spectrometry. Anal Biochem 361:
15–23.
Ouwehand, A.C., Salminen, S., and Isolauri, E. (2002) Pro-
biotics: an overview of beneficial effects. Antonie Van
Leeuwenhoek 82: 279–289.
Parche, S., Beleut, M., Rezzonico, E., Jacobs, D., Arigoni, F.,
Titgemeyer, F., and Jankovic, I. (2006) Lactose-over-
glucose preference in Bifidobacterium longum NCC2705:
HMO metabolism in Bifidobacteria sp. 341
© 2008 The Authors
Journal compilation © 2008 Society for Applied Microbiology and Blackwell Publishing Ltd, Microbial Biotechnology, 2, 333–342
glcP, encoding a glucose transporter, is subject to lactose
repression. J Bacteriol 188: 1260–1265.
Roberfroid, M. (2007) Prebiotics: the concept revisited. J Nutr
137: 830s–837s.
Ruiz-Palacios, G.M., Cervantes, L.E., Ramos, P., Chavez-
Munguia, B., and Newburg, D.S. (2003) Campylobacter
jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta
1, 4GlcNAc), and fucosyloligosaccharides of human milk
inhibit its binding and infection. J Biol Chem 278: 14112–
14120.
Sakata, S., Kitahara, M., Sakamoto, M., Hayashi, H., Fuku-
yama, M., and Benno, Y. (2002) Unification of Bifidobacte-
rium infantis and Bifidobacterium suis as Bifidobacterium
longum. Int J Syst Evol Microbiol 52: 1945–1951.
Sela, D.A., Chapman, J., Adeuya, A., Kim, J.H., Chen, F.,
Whitehead, T.R., et al. (2008) The complete genome
sequence of Bifidobacterium longum subsp. infantis
reveals adaptations for milk utilization within the infant
microbiome. Proc Natl Acad Sci USA 105: 18964–18969.
Servin, A.L. (2004) Antagonistic activities of lactobacilli and
bifidobacteria against microbial pathogens. FEMS Micro-
biol Rev 28: 405–440.
Ward, R.E., Ninonuevo, M., Mills, D.A., Lebrilla, C.B., and
German, J.B. (2006) In vitro fermentation of breast milk
oligosaccharides by Bifidobacterium infantis and Lactoba-
cillus gasseri. Appl Environ Microbiol 72: 4497–4499.
Supporting information
Additional Supporting Information may be found in the online
version of this article:
Fig. S1. Microtitre plate-based growth curves. Growth
curves of all tested strains in a semi-synthetic MRS medium
supplemented with 1.6% (w/v) HMO. Growth was measured
as optical density (OD) of the media at 600 nm. Depending
when each strain reached stationary phase 79, 110 or 133
readings were collected for each sample over the course of
the experiment. Growth curves were constructed by using the
average OD reading for three replicates at each time point.
Controls consisted of inoculated medium lacking HMO and
un-inoculated medium containing HMO which was also used
as a blank for OD measurements.
Fig. S2. HMO consumption glycoprofiles (detailed). MALDI-
FTICR-MS analysis of HMO consumption by 12 bifidobacte-
rial strains grown on a medium supplemented with 1.6% (w/v)
HMO. HMO consumption represented as the per cent differ-
ence in HMO abundance between the start and the end of
fermentation, which was defined as the beginning of station-
ary phase. The five most abundant HMO masses were m/z:
(a) 732.5; (b) 878.3; (c) 1097.4; (d) 1243.4; (e) 1389.5. Fer-
mentations were carried out in triplicate; controls consisted of
inoculated medium lacking HMO and un-inoculated medium
containing HMO which was also used as a blank for OD
measurements. Error bars are standard deviations of the
mean for each available time point.
Table S1. List of possible HMOs, their masses, retention
times and compositions. The analysis was performed using
the HPLC-Chip/TOF-MS system.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
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